Tradestie Institutional Equity Comparison Engine

OKYO vs DRMA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OKYO Overall Edge

OKYO Captures Institutional Edge (2โ€“0 Pillars ยท 5โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to OKYO Pharma Limited Ordinary Shares (OKYO) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, OKYO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus DRMA at N/M Forward P/E and -13082.3% operating margin (+0.0% YoY). In options structure, OKYO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against DRMA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
OKYO N/M vs DRMA N/M Fwd P/E
Growth & Margin Winner OKYO
Op Margin 0.0% vs -13082.3% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner OKYO
1Y -47.0% vs -79.1% ยท 52W Pos 3% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
OKYO NASDAQ
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap $62.7M
1M Return -27.21%
1Y Return -47.03%
Forward P/E N/M
Unified AI Score
42.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 50.0 Mom 45.0
DRMA NASDAQ
Dermata Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.51
-4.23% 1D
Market Cap $2.6M
1M Return -41.03%
1Y Return -79.12%
Forward P/E N/M
Unified AI Score
42.2 / 100 HOLD
Tech 35.0 Fund 42.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OKYO -47.03% DRMA -79.12% Spread: +32.09 pp (OKYO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
OKYO TTM Op. Margin: 0.0% DRMA TTM Op. Margin: -13082.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKYO vs DRMA. Trailing 12-month operating profitability (OKYO 0.0% vs DRMA -13082.3%) and valuation multiples (OKYO N/M vs DRMA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OKYO (5) vs DRMA (1)
Institutional Metric OKYO DRMA Criterion Row Winner
Market Capitalization Scale $62.7M $2.6M Larger Scale OKYO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% -13082.3% Higher Margin OKYO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -263.8% -241.5% Higher ROE DRMA
52-Week Range Position Momentum 3% ($1โ€“$3) 0% ($0โ€“$5) Stronger Trend OKYO
Beta / 30D Volatility Risk Regime 1.00ฮฒ ยท 76% Vol 1.09ฮฒ ยท 105% Vol Lower Realized Risk OKYO
Unified Institutional Score Composite Signal 42.8 / 100 (HOLD) 42.2 / 100 (HOLD) Higher Composite OKYO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OKYO vs DRMA Buy Guide
OKYO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live OKYO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DRMA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live DRMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OKYO nor DRMA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.